Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7286728 | 1.00 | TSHR (0.37) | TSHRALDH1A1EPHX2ATMHCAR2 | |
| SCHEMBL7771226 | 0.94 | NAAA (0.41) | TSHREPHX2HCAR2NAAA | |
| SCHEMBL7297178 | 0.89 | TSHR (0.35) | TSHRALDH1A1EPHX2ATMNAAA | |
| SCHEMBL20165444 | 0.85 | TSHR (0.40) | TSHRALDH1A1ATMCYP1A2CYP3A4 | |
| SCHEMBL5980962 | 0.85 | TSHR (0.40) | TSHRALDH1A1ATMCYP1A2CYP3A4 | |
| SCHEMBL14976393 | 0.84 | ALDH1A1 (0.35) | TSHRALDH1A1EPHX2ATMNAAA | |
| SCHEMBL8759979 | 0.83 | CTSL (0.37) | TSHRALDH1A1EPHX2ATMNAAA | |
| SCHEMBL10526692 | 0.83 | ALDH1A1 (0.34) | TSHRALDH1A1EPHX2ATMNAAA | |
| SCHEMBL6940153 | 0.81 | MAPT (0.41) | TSHRALDH1A1ATM | |
| SCHEMBL14920073 | 0.79 | ALDH1A1 (0.42) | TSHRALDH1A1EPHX2ATMNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |